Research programme: cancer therapeutics - Phylogica
Latest Information Update: 30 Apr 2015
At a glance
- Originator Phoremost; Phylogica
- Mechanism of Action Transcription factor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer